The FDA has approved Sarclisa (isatuximab) in combination with bortezomib, lenalidomide, and dexamethasone for transplant-ineligible, newly diagnosed multiple myeloma.

Analyst Eric Le Berrigaud from Stifel Nicolaus maintained a Buy rating on Sanofi (SNYNF – Research Report) and increased the price target ...

US FDA approves anti-CD38 therapy, Sarclisa in combo with standard-of-care treatment for adult patients with NDMM who are not eligible for transplant: Paris Tuesday, September 24, ...

Approval based on positive results from the IMROZ phase 3 study demonstrating Sarclisa in combination with bortezomib, lenalidomide, and dexamethasone (VRd) significantly improved progression-free ...

The 21st annual meeting of the International Myeloma Society takes place September 25-28, 2024, in Rio de Janiero, Brazil.

And the agency expanded the approval of bimekizumab (Bimzelx) to include psoriatic arthritis, non-radiographic axial spondyloarthritis, and ankylosing spondylitis, UCB Announced.

This latest FDA decision marks the first approval for SNY's Sarclisa as a first-line treatment for multiple myeloma patients.

The FDA approved Sanofi's Sarclisa (isatuximab) in combination with VRd as a first-line treatment for newly diagnosed ...

The FDA has approved Sarclisa (isatuximab) as a first-line therapy for blood cancer multiple myeloma as a combination regimen ...

The US Food and Drug Administration (FDA) has approved Sarclisa (isatuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) as a first line treatment option for adult patients ...

In addition to other MM indications, Isatuximab's anti-CD38 competitor on the US market, daratumumab (Darzalex — Johnson & Johnson), also carries a first-line indication for transplant-ineligible MM ...

This summary highlights major health news, including EU's endorsement of Novo Nordisk's Wegovy for heart conditions in ...